Vertex doesn’t need to do more testing for rogue gene edits from sickle cell therapy trial, FDA advisors say
Just over a month before the FDA makes a landmark decision about the first-ever therapy to use CRISPR/Cas9 gene editing, the agency is paying close …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
